Fig. 9

GCSF neutralization synergizes with Flt3L in vivo to promote cDC1 numbers and function. Tumor-free mice or orthotopic PyMT-B6 tumor-bearing end-stage mice treated with 50 μg anti-GCSF IgGs 3 × /week for 2 weeks and/or 30 μg Flt3L daily for 9 days. End stage is defined in the Methods. a Number of BM pre-DCs, CD24⁺ cDC1s, and Sirpα⁺ cDC2s. b Number of blood pre-DCs and granulocytes. c IRF8 measured in BM MDPs, CDPs, and pre-DCs. d Number of tumor CD103⁺ cDC1s, CD11b⁺ cDC2s, and CD8⁺ T cells (CD45⁺CD3⁺CD8⁺); n = 6/group. e Established 1 cm+ diameter orthotopic PyMT-mCh-OVA mammary tumors were treated with vehicle or Flt3L (30 μg)+anti-PD1 IgGs (200 μg)+intratumoral Poly I:C (50 μg)+/− anti-GCSF IgGs (50 ng) according to the displayed treatment schedule. Survival to 2.3 cm³ tumor volume. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not significant by unpaired two-sided Student’s t test. Log-rank (Mantel–Cox) p value is denoted for differences in survival